Leone Beagley
Overview
Explore the profile of Leone Beagley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
657
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neller M, Ambalathingal G, Hamad N, Sasadeusz J, Pearson R, Holmes-Liew C, et al.
Nat Commun
. 2024 Dec;
15(1):10339.
PMID: 39627190
Adoptive T-cell immunotherapy holds great promise for the treatment of viral complications in immunocompromised patients resistant to standard anti-viral strategies. We present a retrospective analysis of 78 patients from 19...
2.
Ranganathan D, Leibowitz S, John G, Neller M, Ambalathingal G, Beagley L, et al.
Clin Transl Immunology
. 2024 Nov;
13(11):e70015.
PMID: 39564002
Objectives: Dysregulation of Epstein-Barr virus (EBV)-specific cellular immunity has been hypothesised as one of the contributing factors in the pathogenesis of systemic lupus erythematosus (SLE). Lupus nephritis is a major...
3.
Panikkar A, Lineburg K, Raju J, Chew K, Ambalathingal G, Rehan S, et al.
PLoS Pathog
. 2022 Feb;
18(2):e1010339.
PMID: 35157735
Adoptive T-cell immunotherapy has provided promising results in the treatment of viral complications in humans, particularly in the context of immunocompromised patients who have exhausted all other clinical options. The...
4.
Pender M, Csurhes P, Smith C, Douglas N, Neller M, Matthews K, et al.
JCI Insight
. 2020 Oct;
5(20).
PMID: 33055421
No abstract available.
5.
Smith C, Lineburg K, Martins J, Ambalathingal G, Neller M, Morrison B, et al.
J Clin Invest
. 2020 Aug;
130(11):6041-6053.
PMID: 32750039
BACKGROUNDThe recent failure of checkpoint-blockade therapies for glioblastoma multiforme (GBM) in late-phase clinical trials has directed interest toward adoptive cellular therapies (ACTs). In this open-label, first-in-human trial, we have assessed...
6.
Smith C, Corvino D, Beagley L, Rehan S, Neller M, Crooks P, et al.
J Clin Invest
. 2019 Aug;
129(11):5020-5032.
PMID: 31415240
BACKGROUNDImpaired T cell immunity in transplant recipients is associated with infection-related morbidity and mortality. We recently reported the successful use of adoptive T cell therapy (ACT) against drug-resistant/recurrent cytomegalovirus in...
7.
Pender M, Csurhes P, Smith C, Douglas N, Neller M, Matthews K, et al.
JCI Insight
. 2018 Nov;
3(22).
PMID: 30429369
Background: Increasing evidence indicates a role for EBV in the pathogenesis of multiple sclerosis (MS). EBV-infected autoreactive B cells might accumulate in the CNS because of defective cytotoxic CD8+ T...
8.
Smith C, Beagley L, Rehan S, Neller M, Crooks P, Solomon M, et al.
Clin Infect Dis
. 2018 Jul;
68(4):632-640.
PMID: 29982441
Background: Opportunistic infections including cytomegalovirus (CMV) are a major cause of morbidity and mortality in solid organ transplant (SOT) recipients. The recurrent and protracted use of antiviral drugs with eventual...
9.
Smith C, Lee V, Schuessler A, Beagley L, Rehan S, Tsang J, et al.
Oncoimmunology
. 2017 Mar;
6(2):e1273311.
PMID: 28344888
Adoptive T cell therapy has emerged as a powerful strategy to treat human cancers especially haematological malignancies. Extension of these therapies to solid cancers remains a significant challenge especially in...
10.
Pierucci P, Malouf M, Glanville A, Beagley L, Smith C, Khanna R
J Heart Lung Transplant
. 2016 Apr;
35(5):685-7.
PMID: 27083238
No abstract available.